Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

doi:10.1200/JCO.2013.54.4973

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Feb 2015

Röllig Christoph, Bornhäuser Martin, Kramer Michael, Thiede Christian, Ho Anthony D, Krämer Alwin, Schäfer-Eckart Kerstin, Wandt Hannes, Hänel Mathias, Einsele Hermann, Aulitzky Walter E, Schmitz Norbert, Berdel Wolfgang E, Stelljes Matthias, Müller-Tidow Carsten, Krug Utz, Platzbecker Uwe, Wermke Martin, Baldus Claudia D, Krause Stefan W, Stölzel Friedrich, von Bonin Malte, Schaich Markus, Serve Hubert, Schetelig Johannes, Ehninger Gerhard

Abstract excerpt

PURPOSE: The presence of a mutated nucleophosmin-1 gene (NPM1(mut)) in acute myeloid leukemia (AML) is associated with a favorable prognosis. To assess the predictive value with regard to allogeneic stem-cell transplantation (SCT), we compared the clinical course of patients with NPM1(mut) AML eligible for allogeneic SCT in a donor versus no-donor analysis. PATIENTS AND METHODS: Of 1,179 patients with AML (age 18...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Histocompatibility Testing

Share to Nucleophosmin

Share to Siblings

Share to Tissue Donors

Share to Transplantation, Autologous

Share to Transplantation, Homologous

Source

Open in PubMed

Identifiers

PMID: 25547501
DOI: 10.1200/JCO.2013.54.4973

Genes

NPM1
SCT
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.PMID 25547501Read ↗

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia – a single center experience –Semantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.Semantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemiaSemantic proximity Read ↗

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.Semantic proximity Read ↗

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.Semantic proximity Read ↗

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Semantic proximity Read ↗

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort StudySemantic proximity Read ↗

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.Semantic proximity Read ↗

A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.Semantic proximity Read ↗

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.